Community-acquired Pneumonia Clinical Trial
— R3POfficial title:
Development of a Risk Prediction Model for Identifying Potentially Avoidable Readmissions of Patients Hospitalized With Community-Acquired Pneumonia
Verified date | May 2022 |
Source | University Hospital, Grenoble |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
From 10% to 30% of patients hospitalized with community-acquired pneumonia (CAP) are readmitted within 30 days of discharge. These readmissions have negative consequences for the patients and the hospitals where they are treated, including impaired quality of life, exposure to hospital-related adverse events, and increased resource utilization. Risk-adjusted readmission rates can be easily computed and tracked from computerized hospital discharge data, using validated models. As part of the Hospital Readmission Reduction Program (HRRP) effective in fiscal year 2013, United States hospitals with higher than expected 30-day readmission rates after pneumonia hospitalization have been subject to financial penalties from the Center for Medicare and Medicaid Services (CMS). The underlying logic of the HRRP is based upon the notion that short-term readmission is often a preventable adverse outcome, reflecting suboptimal quality of care during index hospitalization. Yet, published evidence suggests that less than one in four all-cause readmissions are deemed avoidable. Because only avoidable readmissions can be influenced by interventions designed to decrease readmission rates, avoidable readmission is a more relevant metric than all-cause readmission for tracking quality of hospital care for pneumonia. The purpose of this study is to develop an administrative data-based risk prediction model for identifying potentially avoidable readmissions within 30 days of discharge for patients hospitalized with CAP. R3P is a retrospective observational cohort study of consecutive adult patients discharged from two hospitals with a diagnosis code of CAP. Data sources include routinely collected hospital discharge data and retrospective chart reviews.
Status | Completed |
Enrollment | 1150 |
Est. completion date | January 1, 2022 |
Est. primary completion date | September 1, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion criteria Adult patient hospital discharges with: - a primary ICD-10 diagnosis code of pneumonia - or a secondary diagnosis code of pneumonia with a primary diagnosis code of respiratory failure or sepsis. Exclusion criteria - Patient admitted from another acute care facility - Patient transferred to another acute care facility - Patient admitted in day care unit |
Country | Name | City | State |
---|---|---|---|
France | Grenoble University Hospital CS10217 Grenoble Cedex 9 | Grenoble | |
France | Centre Hospitalier Annecy Genevois,1 avenue de l'hôpital, Epagny Metz-Tessy,BP 90074 | Pringy |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Grenoble | Centre Hospitalier Annecy Genevois |
France,
Halfon P, Eggli Y, van Melle G, Chevalier J, Wasserfallen JB, Burnand B. Measuring potentially avoidable hospital readmissions. J Clin Epidemiol. 2002 Jun;55(6):573-87. — View Citation
Jasti H, Mortensen EM, Obrosky DS, Kapoor WN, Fine MJ. Causes and risk factors for rehospitalization of patients hospitalized with community-acquired pneumonia. Clin Infect Dis. 2008 Feb 15;46(4):550-6. doi: 10.1086/526526. — View Citation
Lindenauer PK, Normand SL, Drye EE, Lin Z, Goodrich K, Desai MM, Bratzler DW, O'Donnell WJ, Metersky ML, Krumholz HM. Development, validation, and results of a measure of 30-day readmission following hospitalization for pneumonia. J Hosp Med. 2011 Mar;6(3):142-50. doi: 10.1002/jhm.890. Epub 2011 Jan 5. — View Citation
Skull SA, Andrews RM, Byrnes GB, Campbell DA, Nolan TM, Brown GV, Kelly HA. ICD-10 codes are a valid tool for identification of pneumonia in hospitalized patients aged > or = 65 years. Epidemiol Infect. 2008 Feb;136(2):232-40. Epub 2007 Apr 20. — View Citation
van Walraven C, Bennett C, Jennings A, Austin PC, Forster AJ. Proportion of hospital readmissions deemed avoidable: a systematic review. CMAJ. 2011 Apr 19;183(7):E391-402. doi: 10.1503/cmaj.101860. Epub 2011 Mar 28. Review. — View Citation
van Walraven C, Jennings A, Taljaard M, Dhalla I, English S, Mulpuru S, Blecker S, Forster AJ. Incidence of potentially avoidable urgent readmissions and their relation to all-cause urgent readmissions. CMAJ. 2011 Oct 4;183(14):E1067-72. doi: 10.1503/cmaj.110400. Epub 2011 Aug 22. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Potentially avoidable readmission | 30 days | ||
Secondary | All-cause readmission | 30 days | ||
Secondary | All-cause readmission | 1 year | ||
Secondary | All-cause mortality | 1 year | ||
Secondary | Composite of all-cause mortality and readmission | 30 days | ||
Secondary | Intensive care unit admission | 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05722938 -
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
|
Phase 3 | |
Terminated |
NCT04972318 -
Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia
|
N/A | |
Recruiting |
NCT06065618 -
Characteristics of Hospitalized Patients With Community-acquired Pneumonia
|
||
Not yet recruiting |
NCT03675178 -
Clinical Study of Anerning Particle for the Treatment of Childhood Community-acquired Pneumonia
|
Phase 4 | |
Not yet recruiting |
NCT04166110 -
Antibiotic Therapy In Respiratory Tract Infections
|
N/A | |
Completed |
NCT02380352 -
Short-course Antimicrobial Therapy for Paediatric Respiratory Infections
|
Phase 4 | |
Completed |
NCT01671280 -
Drug Use Investigation Of Azithromycin IV For Community-Acquired Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan)
|
N/A | |
Completed |
NCT02555852 -
Proton Pump Inhibitors and Risk of Community-acquired Pneumonia
|
N/A | |
Recruiting |
NCT00752947 -
Efficacy and Safety Trial to Assess Moxifloxacin in Treating Community-Acquired Pneumonia (CAP) With Aspiration Factors
|
Phase 4 | |
Completed |
NCT00140023 -
Azithromycin Microspheres in Patients With Low Risk Community Acquired Pneumonia
|
Phase 3 | |
Recruiting |
NCT04089787 -
Shortened Antibiotic Treatment of 5 Days in Community-Acquired Pneumonia
|
Phase 4 | |
Completed |
NCT05356494 -
Postural Drainage and PEP Technique in Community Acquired Pneumonia
|
N/A | |
Completed |
NCT05133752 -
Oral Nemonoxacin in Treating Elderly Patients With CAP
|
Phase 4 | |
Not yet recruiting |
NCT06291012 -
Stopping Pneumonia Antibiotherapy Regimen Early
|
Phase 4 | |
Recruiting |
NCT05002192 -
A Retrospective, Real-world Study of ELP Used in the Expectorant Treatment of Community-acquired Pneumonia
|
||
Completed |
NCT03452826 -
Combined Use of a Respiratory Broad Panel mPCR and Procalcitonin to Reduce Duration of Antibiotics Exposure in Patients With Severe Community-Acquired Pneumonia
|
N/A | |
Terminated |
NCT04071041 -
Effect of Albumin Administration in Hypoalbuminemic Hospitalized Patients With Community-acquired Pneumonia.
|
Phase 3 | |
Completed |
NCT03474991 -
KIDS-STEP_Betamethasone Therapy in Hospitalised Children With CAP
|
Phase 3 | |
Withdrawn |
NCT01662258 -
Microbiology Testing With the Aim Of Directed Antimicrobial Therapy For CAP
|
N/A | |
Completed |
NCT01723644 -
Clinical Reassessment Versus Procalcitonin in Order to Shorten Antibiotic Duration in Community-acquired Pneumonia
|
N/A |